Come by poster 5026 tonight to hear about how pharmacists can help you optimally manage your leukemia patients! @huntsmancancer @HCIoncopharm
Latest posts 5
👯♀️
Happening now! @CWagnerPharmD and @TaylorKujawa are presenting at HOPA Annual Conference and “Debating the incorporation of novel therapies in front line treatment for acute lymphoblastic leukemia treatment” @HOPArx #HOPA2024View quoted post on X
Had some wonderful discussions at learned a lot at #ASH23 - special thanks to @MyelomaSLC for continued support and mentorship!
With the completion of #ASH2023 we wanted to highlight some fantastic work by our very own @CWagnerPharmD! Thanks for representing @huntsmancancer & @huntsmanMM with important RWE work and collaboration via the US MM Immunotherapy Consortium. Check it out! ashpublications.org/blood/article/…View quoted post on X
🚨Midostaurin with idarubicin-based 7+3 induction yields a CR rate of 73%, EFS of 11.7 months and no concerning toxicities. IDA 12 mg/m2 is a suitable alternative to DNR 60 mg/m2 in FLT3-mutated AML receiving 7+3+Midostaurin. @jsleerx FABULOUS job! haematologica.org/article/view/h…
#oncopharm colleagues, do you typically do same-day or next-day pegfilgrastim administration with ADCs (I.e. brentuximab vedotin, trastuzumab emtansine, etc.) @kczmj @thisisJamesD @ChristTrevor let me know your thoughts!
- Same-day 2
- Next-day 18